Price movement over the last 24 hours
Applovin Corporation vs Johnson & Johnson — how do they compare? Applovin Corporation trades at $507.47 (market cap $170.31B), while Johnson & Johnson trades at $258.58 (market cap $618.61B). The key difference: Johnson & Johnson is far larger — about 3.6× Applovin Corporation's market cap, and Johnson & Johnson pays a 2.09% dividend while Applovin Corporation pays none. Which is the better fit depends on your goals.
| APP | JNJ | |
|---|---|---|
Market Cap | $170.31B | $618.61B |
Sector | Technology | Health |
52-Week High | $733.60 | $267.24 |
52-Week Low | $335.10 | $155.17 |
Enterprise Value | $171.07B | $651.54B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.09% |
Signals from Pluang's Aura AI — not financial advice
AppLovin trades at $506.98, down 2.58% today, with a bullish technical setup near pivot point support at $504. The company shows exceptional fundamentals with 59% revenue growth in Q1 2026 and net margins exceeding 64%. Analyst consensus remains strongly bullish with an $644.09 price target, supported by expanding e-commerce advertising share and AI-driven platform growth noted in recent Jefferies research.
The outlook remains positive given consistent earnings beats and projected revenue growth to $6.2B in 2026. Primary risks include premium valuation multiples (P/E 44.09) and competitive pressure in mobile advertising. The stock offers growth exposure but requires monitoring of execution against high expectations.
Johnson & Johnson (JNJ) trades at $256.98, down 0.82% today, with a bullish technical signal from moving averages and a consensus analyst price target of $268.50. The company reported strong Q1 2026 EPS of $2.70, beating expectations, and maintains robust profitability with a net income margin of 21.83%. Recent news highlights dividend growth strategies and comparisons with peers like AbbVie, while cash flow trends show operational strength despite negative net cash flow in 2025.
JNJ presents a stable investment opportunity with consistent earnings beats and a solid dividend, but faces risks from rising debt levels and competitive pressures. The stock's current valuation metrics, including a P/E of 29.78, suggest it is fairly valued with moderate upside potential based on analyst targets. Investors should weigh the company's strong fundamentals against macroeconomic and sector-specific headwinds.
Trailing returns across standard periods
Latest headlines on both assets
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →